open access

Vol 70, No 1 (2019)
Original papers
Published online: 2018-10-30
Submitted: 2018-07-29
Accepted: 2018-10-08
Get Citation

The role of adiponectin and leptin in the treatment of ovarian cancer patients

Grzegorz J. Słomian, Damian Nowak, Marta Buczkowska, Anna Głogowska-Gruszka, Szymon P. Słomian, Wojciech Roczniak, Szymon Janyga, Przemysław Nowak
DOI: 10.5603/EP.a2018.0081
·
Pubmed: 30450532
·
Endokrynologia Polska 2019;70(1):57-63.

open access

Vol 70, No 1 (2019)
Original papers
Published online: 2018-10-30
Submitted: 2018-07-29
Accepted: 2018-10-08

Abstract

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy.

Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin and leptin concentrations were determined in the blood serum.

Results: The average adiponectin concentration before chemotherapy was found to be 8.83 ± 3.19 μg/ml, as compared to 10.37 ± 4.18 μg/ml (increase by 17.44%, p < 0.001) after treatment. Mean pre-treatment leptin concentration was 16.89 ± 15.54 ng/ml, and 21.77 ± 14.69 ng/ml after chemotherapy (increase by 28.89%, p < 0.01). A positive correlation was found between leptin concentration and age and BMI. There was no relationship of the disease severity with the response to treatment and the concentration of the adipokines. The leptin/adiponectin ratio (L/A) before treatment correlated with better response to chemotherapy.

Conclusions: Adiponectin and leptin did not correlate with the stage of ovarian cancer and response to chemotherapy. The L/A ratio may be considered a predictor of clinical response to treatment.

Abstract

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy.

Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin and leptin concentrations were determined in the blood serum.

Results: The average adiponectin concentration before chemotherapy was found to be 8.83 ± 3.19 μg/ml, as compared to 10.37 ± 4.18 μg/ml (increase by 17.44%, p < 0.001) after treatment. Mean pre-treatment leptin concentration was 16.89 ± 15.54 ng/ml, and 21.77 ± 14.69 ng/ml after chemotherapy (increase by 28.89%, p < 0.01). A positive correlation was found between leptin concentration and age and BMI. There was no relationship of the disease severity with the response to treatment and the concentration of the adipokines. The leptin/adiponectin ratio (L/A) before treatment correlated with better response to chemotherapy.

Conclusions: Adiponectin and leptin did not correlate with the stage of ovarian cancer and response to chemotherapy. The L/A ratio may be considered a predictor of clinical response to treatment.

Get Citation

Keywords

adiponectin; leptin; chemotherapy; ovarian neoplasm

About this article
Title

The role of adiponectin and leptin in the treatment of ovarian cancer patients

Journal

Endokrynologia Polska

Issue

Vol 70, No 1 (2019)

Pages

57-63

Published online

2018-10-30

DOI

10.5603/EP.a2018.0081

Pubmed

30450532

Bibliographic record

Endokrynologia Polska 2019;70(1):57-63.

Keywords

adiponectin
leptin
chemotherapy
ovarian neoplasm

Authors

Grzegorz J. Słomian
Damian Nowak
Marta Buczkowska
Anna Głogowska-Gruszka
Szymon P. Słomian
Wojciech Roczniak
Szymon Janyga
Przemysław Nowak

References (30)
  1. Romanidis K, Nagorni EA, Halkia E, et al. The role of cytoreductive surgery in advanced ovarian cancer: the general surgeon's perspective. J BUON. 2014; 19(3): 598–604.
  2. Kalliala I, Markozannes G, Gunter MJ, et al. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ. 2017; 359: j4511.
  3. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006; 29(1): 81–90.
  4. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 2017; 18(6).
  5. Oswiecimska JM, Roczniak W, Roczniak RG, et al. Serum adiponectin levels in adolescents and young adults with growth hormone deficiency. Neuro Endocrinol Lett. 2017; 38(2): 107–116.
  6. Wojciechowska C, Jacheć W, Romuk E, et al. The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy. Endokrynol Pol. 2017; 68(1): 26–34.
  7. Baranowska-Bik A, Baranowska B, Martyńska L, et al. Adipokine profile in patients with anorexia nervosa. Endokrynol Pol. 2017; 68(4): 422–429.
  8. Krysiak R, Żmuda W, Marek B, et al. Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynologia Polska. 2015.
  9. Ziora-Jakutowicz K, Zimowski J, Ziora KT, et al. Genetic polymorphisms and serum concentrations of adiponectin and resistin in anorexia nervosa and healthy controls - pilot study. Neuro Endocrinol Lett. 2017; 38(3): 215–223.
  10. Stoll BA. Obesity and breast cancer. Int J Obes Relat Metab Disord. 1996; 20(5): 389–392.
  11. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3(9): 565–574.
  12. Siemińska L, Borowski A, Marek B, et al. Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol. 2018; 69(2): 120–127.
  13. Choi JH, Park SH, Leung PCK, et al. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2005; 90(1): 207–210.
  14. Schäffler A, Schölmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer — endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 2007; 3(4): 345–354.
  15. Jeong YJ, Bong JG, Park SH, et al. Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. J Breast Cancer. 2011; 14(2): 96–103.
  16. Macis D, Gandini S, Guerrieri-Gonzaga A, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol. 2012; 30(2): 151–157.
  17. Słomian G, Świętochowska E, Malinowska-Borowska J, et al. Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep. 2014; 66(5): 902–907.
  18. Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015; 21(1): 57–74.
  19. Tessitore L, Vizio B, Pesola D, et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol. 2004; 24(6): 1529–1535.
  20. Serin IS, Tanriverdi F, Yilmaz MO, et al. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 2008; 24(3): 117–121.
  21. Jin JH, Kim HJ, Kim CY, et al. Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer. Obstet Gynecol Sci. 2016; 59(4): 279–285.
  22. Diaz ES, Karlan BY, Li AJ. Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. Gynecol Oncol. 2013; 129(2): 353–357.
  23. Grabowski J. Ocena stężeń leptyny w surowicy krwi chorych na raka jajnika a skuteczność cytoredukcji i chemioterapii. Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań 2009.
  24. Słomian G, Świętochowska E, Nowak G. Chemotherapy and plasma adipokines level in patients with colorectal cancer. Postepy Hig Med Dosw. 2017; 71: 281–290.
  25. Dalamaga M, Karmaniolas K, Papadavid E, et al. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause. 2011; 18(11): 1198–1204.
  26. Dalamaga M, Archondakis S, Sotiropoulos G, et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas. 2012; 71(3): 301–308.
  27. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012; 33(4): 547–594.
  28. Wauman J, Tavernier J. Leptin receptor signaling: pathways to leptin resistance. Front Biosci (Landmark Ed). 2011; 16: 2771–2793.
  29. Kumar J, Fang H, McCulloch DR, et al. Leptin receptor signaling via Janus kinase 2/Signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes. Oncotarget. 2017; 8(55): 93530–93540.
  30. Patel HJ, Patel BM. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017; 170: 56–63.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl